Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBIT (2016 - 2023)

Historic EBIT for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $53.8 million.

  • RedHill Biopharma's EBIT rose 48687.63% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$44.0 million, marking a year-over-year increase of 5531.84%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 11568249392.02% down from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's EBIT is $53.8 million, which was up 48687.63% from -$29.1 million recorded in Q1 2023.
  • Over the past 5 years, RedHill Biopharma's EBIT peaked at $53.8 million during Q2 2023, and registered a low of -$141.6 million during Q4 2021.
  • In the last 5 years, RedHill Biopharma's EBIT had a median value of $12.4 million in 2019 and averaged $421000.0.
  • As far as peak fluctuations go, RedHill Biopharma's EBIT plummeted by 81834.28% in 2021, and later soared by 48687.63% in 2023.
  • Over the past 5 years, RedHill Biopharma's EBIT (Quarter) stood at $11.8 million in 2019, then surged by 67.53% to $19.7 million in 2020, then tumbled by 818.34% to -$141.6 million in 2021, then skyrocketed by 46.5% to -$75.7 million in 2022, then soared by 170.97% to $53.8 million in 2023.
  • Its EBIT stands at $53.8 million for Q2 2023, versus -$29.1 million for Q1 2023 and -$75.7 million for Q4 2022.